Abstract
No public abstract is available from the verified source records.
Nichola Cooper, David J Kuter, Henrik Frederiksen, Joan Cid, Catherine M Broome, Miriam Vara Pampliega, Amitabha Mazumder, Alessandro Lucchesi, Antonio Risitano, Sumit Sawhney, Quentin A Hill, Deepthi Jayawardene, Heidi Krenz, Ahmed Daak
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
How I treat warm autoimmune hemolytic anemia
10.1182/blood.2019003808 · 2021
Warm autoimmune hemolytic anemia and the best treatment strategies
10.1182/hematology.2022000405 · 2022
The chemokines IP-10/CXCL10 and IL-8/CXCL8 are potential novel biomarkers of warm autoimmune hemolytic anemia
10.1182/bloodadvances.2021006797 · 2023
Role of inflammation in human fatigue: relevance of multidimensional assessments and potential neuronal mechanisms
10.3389/fimmu.2017.00021 · 2017
Red cell DAMPs and inflammation
10.1007/s00011-016-0955-9 · 2016
Exploring patients' experiences with wAIHA and the content validity of the FACIT-fatigue: a qualitative interview study
10.1186/s13023-025-03767-4 · 2025
Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting
10.1016/j.blre.2019.100648 · 2020
Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients
10.1002/ajh.23767 · 2014
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1111/bjh.12541 · 2013
A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)
10.1002/ajh.24570 · 2017
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
10.1182/blood.2024027336 · 2025
Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia
10.1056/nejmoa2110297 · 2022
Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease
10.4049/jimmunol.2001130 · 2021
Bruton tyrosine kinase inhibitor rilzabrutinib reduces vaso-occlusion and markers of inflammation and adhesion in transgenic mice with sickle cell disease
10.1182/blood-2024-200182 · 2024
Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice
10.1182/bloodadvances.2024012713 · 2024
Impact of rilzabrutinib on biomarkers of inflammation and complement factors in warm autoimmune hemolytic anemia (wAIHA): results from the phase 2 study
2025
Content validity and meaningful change for the FACIT-Fatigue scale in warm autoimmune hemolytic anemia: results from qualitative interview studies with patients
10.1186/s41687-025-00930-0 · 2025
Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
10.1016/s0885-3924(96)00274-6 · 1997
Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease
10.3390/cancers13051103 · 2021
Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study
10.1111/j.1365-2796.2009.02126.x · 2009
Management of autoimmune hemolytic anemia
10.1182/hematology.2025000719 · 2025
Fostamatinib for warm antibody autoimmune hemolytic anemia: phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD)
10.1002/ajh.27144 · 2024
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: phase 2, multicenter, open-label study
10.1002/ajh.26508 · 2022
Thrombotic complications in patients with immune-mediated hemolysis
10.3390/jcm10081764 · 2021
The emerging role of NETs in venous thrombosis and immunothrombosis
10.3389/fimmu.2016.00236 · 2016
Evaluating rilzabrutinib in the treatment of immune thrombocytopenia
10.1080/1750743x.2025.2545170 · 2025
Impact of rilzabrutinib on gene expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the phase 2B LUMINA 2 study
10.1182/blood-2025-2881 · 2025
Developing the evidence base for the management of autoimmune haemolytic anaemia (AIHA): the UK experience
10.1111/bjh.17217 · 2021
No additional external references are available.